- Australia frets over Meta halt to US fact-checking
- Japan startup hopeful ahead of second moon launch
- Ukraine allies to hold last defence meet before Trump takes office
- NBA-best Cavs win 11th in a row to end 15-game Thunder streak
- What you need to know about HMPV
- Venezuela braces for crunch anti-Maduro protests
- Bangladesh garment industry rebounds, but workers say little change
- Asian markets drop as trades fret over US inflation, rates outlook
- Mozambique opposition leader due home amid tension over disputed vote
- Doping and a match made in heaven: Australian Open storylines
- Australia recall McSweeney for Sri Lanka Tests, Connolly set for debut
- Myanmar military adopts anti-junta fighters' drone tactics
- Lebanon set to finally elect president after two-year vacancy
- New twist in US-Cuba trademark fight over Havana Club rum
- CES tech looks to help world's aging population
- Venezuela repression increases ahead of crunch anti-Maduro protests
- Rubber tappers forge sustainable future in Amazon
- 'No more fires,' demand fed-up Amazon residents
- Assault on Chad presidential complex leaves 19 dead
- Crowds throng as Jesus statue parades through Philippine capital
- Slot fumes after Spurs teenager Bergvall avoids red card to sink Liverpool
- Fighting at Chad presidency leaves 19 dead, several injured
- US astronauts upbeat seven months into eight-day mission
- Bergvall strikes as Spurs snatch League Cup semi-final lead over Liverpool
- Extreme weather, suburban sprawl fuel LA's wildfires
- Campaigners fear spike in hate speech as Meta lifts restrictions
- Yakuza leader pleads guilty in US court to conspiring to sell nuclear material
- Barcelona defeat Bilbao without Olmo to reach Spanish Super Cup final
- Displaced LA residents in shock at scale of fire destruction
- Gunfire erupts inside presidency in Chad capital
- Miami and Tampa to host outdoor NHL contests in 2026
- Popov claims first World Cup win in Madonna di Campiglio slalom
- Tottenham star Bentancur 'conscious' after head injury in Liverpool clash
- NHL Kings postpone game while NFL monitors LA area wildfires
- Barcelona defeat Athletic without Olmo to reach Spanish Super Cup final
- Bulgaria's Popov claims first World Cup win in Madonna di Campiglio slalom
- Niemann and Nicolai Hojgaard accept special Masters invitations
- Political chess or true beliefs? Zuckerberg's surprise Trump pivot
- Hosszu, swimming's 'Iron Lady', retires at 35
- US withholds $3.6 mln payment to WADA after no audit
- Venezuela opposition decry crackdown before Maduro swearing-in
- US Fed officials concerned over 'stalled' disinflation, tariffs: minutes
- Whole streets burn as fires rage around Los Angeles
- Celebrities flee Los Angeles fires as Hollywood events scrapped
- Several US Fed officials concerned over 'stalled' disinflation: minutes
- Kiwi blaster Guptill retires from international cricket
- Celebrities flee Los Angeles blazes as Hollywood premieres scrapped
- Meta's 'Musk playbook' fans misinformation concerns
- Dani Olmo cleared to play for Barcelona by Spanish sports council
- Man Utd's Maguire given driving ban for speeding
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
A.Gasser--BTB